Abstract: A recombinant attenuated vaccine against infectious bursal disease virus (IBDV) was administered in ovo to 18-day-old embryos. The vaccine was genetically tailored to protect from challenges in the field against classic and variant strains of IBDV. The vaccine virus contains neutralizing epitopes from both classic (D78) and variant strain (GLS), and abrogates expression of the nonstructural protein, VP5 of IBDV. Specificpathogen-free (SPF) and fertile broiler eggs obtained from a local poultry farm were vaccinated and used to evaluate protection against IBDV-STC challenge. A full dose of the vaccine consisting of 5.6x10 plaque 3 forming units (pfu) was administered to SPF and broiler embryos. In addition, a half dose of the vaccine containing 2.3x10 pfu 21 was injected into SPF embryos. The vaccine had no effect on hatchability or first 3 week survival in either broilers or SPF birds, even when high doses were administered. The vaccine generated high antibody titers in chickens with either dosage. All vaccinated groups were protected against mortality. The vaccine did not cause bursal damage and fully protected SPF chickens vaccinated in ovo with half dose of the vaccine and broiler chicks that received a full dose of the recombinant vaccine in ovo.
Introduction
Infectious bursal disease (IBD) is an acute, contagious disease caused by a double-stranded RNA virus of the Birnaviridae family, IBDV. IBDV genome consists of two segments, A and B. The larger segment A contains two overlapping open reading frame (ORF) that encodes a polyprotein VP2-VP4-VP3 and a nonstructural protein, VP5. Segment B encodes a 97-kDa protein, designated VP1, which represents the viral RNA-dependent RNA polymerase. The virus targets the lymphoid tissue of chickens mainly the BF, causing severe bursal damage, and consequently immunosuppression. Thus, IBD is of major economic importance to the poultry industry. A strategy for the control of IBD in chicks involves hyper immunization of breeders, which allows them to transmit high levels of maternal antibodies to progeny during the critical first few weeks of life. Although maternal antibodies provide protection during this period, continued protection against IBDV must be maintained before the maternal immunity reaches sub-protective levels by the administration of live vaccines. However, maternal antibodies can neutralize vaccine virus and reduce the viral load needed to induce immunity (Sharma, 1987) . In addition, new antigenic variants of IBDV, which appeared during the 1980's, introduced new problems for poultry production. These new field isolates were able to break through neutralizing maternal antibodies induced by standard IBDV vaccines (Snyder et al., 1992) . Since then, these variant strains have been incorporated into commercial inactivated vaccines for broiler breeders. Unfortunately, despite these vaccination measures, IBDV continues to be a problem. Very virulent strains of IBDV, have caused outbreaks of disease with high mortality in Europe and Asia (Nunoya et al., 1992; Van den Berg et al., 1991) despite vaccination programs. In addition, live vaccines that are available for mass vaccination of broilers in the first few weeks of life are not suitable for in ovo administration.
These vaccines may induce immunosuppression during late stages of incubation, when the embryo is highly susceptible to infection. Therefore, in an effort to aid in the control of this disease, a recombinant IBD vaccine virus that can protect against both classical and variant strains was created in our laboratory, using reverse genetics system (Liu, 2003) . This virus, designated as rD78GLSNSÄ, is deficient in the expression of VP5 nonstructural protein (NS). I t grows one log lower than the parental viruses, and exhibits decreased cytotoxic and apoptotic effects in cell culture. This virus fails to induce any pathological lesions in the bursa of infected three-week-old chickens. In a ddition, vaccinated birds challenged with classic (STC) a nd variant (GLS) strains of IBDV were fully protected. In this report, we evaluate the potential use of this recombinant attenuated virus in ovo to protect SPF as were utilized for treatment groups A, B, and E
Materials and Methods

Cells and viruses:
Vero cells were maintained i n medium 199 (M199) supplemented with 5% fetal bovine serum (FBS) at 37 C in a humidified 5% CO incubator o 2
and used for propagation of the virus. Primary chicken embryo fibroblast (CEF) cells were prepared a s described previously (Mundt and Vakharia, 1996) . Briefly, ten-day-old embryos from SPF chickens were aseptically removed and cut into pieces. The tissues were rinsed in HBSS and digested with 0.2% trypsin at 37 C for one h o to produce a single cell suspension. The suspension was filtered through gauze and washed twice with HBSS. The cells were grown in M199 and F10 (1:1 v/v) with 10% FBS. Secondary CEF cells, used for virus titration, were maintained in growth medium consisting of M199 and F10 with 5% FBS.
Propagation and purification of IBDV:
The recombinant IBD v accine virus, rD78GLSNSÄ, was prepared a s described (Liu, 2003) . Large amounts of this virus were grown in Vero cells as stock for in ovo inoculations, and stored at -20 C.
o Plaque assays: Virus stocks propagated in cell culture were titered by plaque assay as described earlier (Mundt and Vakharia, 1996) . Briefly, the infected supernatant was diluted in ten-fold increments in MEM without fetal calf serum (FCS). Confluent monolayers of CEFs were -4 -7
3
(vaccinated) because of a possible adverse effect due to vaccination. Sample size was calculated accordingly to protocol previously approved. SPF and commercial fertile broiler eggs of 18 days of embryonation were inoculated using a full dose of rIBDV (group A, and E). Each embryo received 5.6x10 pfu/0.2 mL o f 3 rD78GLSNSÄ. Another group of SPF eggs received only half a dose of this virus, which was 2.3x10 pfu/0.2 mL 3 (group B). The negative controls consisted of nonvaccinated, unchallenged SPF and commercial embryos (groups D, and G). The challenge control groups consisted of SPF and commercial eggs, which did not receive the vaccine and were challenged two weeks post-vaccination (groups C, and F). After in ovo vaccination, all eggs were sealed with adhesive tape and re-incubated. The S PF embryos were free of any other immunosuppressive diseases that could compromise our results, such as adenoviruses, and chicken anaemia virus. The commercial eggs were obtained from Sunrise farms, Catskill, NY. After 21 days of incubation, all hatched chicks were housed in BL-2 isolators at Gudelsky Veterinary Center, University of Maryland. Two weeks post-hatch, all birds were bled and challenged with STC strain (0.2 mL by the ocular and nasal route -10 EID ) of IBDV, except group 3 50 D, and G. At ten days post-challenge, all the remaining birds were anesthetized, bled, and humanely euthanized. Spleen and bursa were collected and bursa/body weight recorded. The bursae were sectioned hatchability in this experiment is much higher than the in half. Spleen and bursa halves were placed in 10% average observed in the poultry industry (83%) because buffered formalin for histology. The other half of the all u nviable eggs were discarded prior to in ovo bursa was stored frozen for later testing by antigen vaccination. capture-ELISA (AC-ELISA). The antibody levels in serum samples collected at 2
Vaccine protection: Results of the IBDV challenge weeks post-vaccination, and 10 days post-challenge, studies are shown in Table 2 . All vaccinated birds were were determined by ELISA and virus neutralization (VN).
fully protected against IBDV-STC. The bursa/body weight A commercial ELISA kit was used (Synbiotics, San ratio was calculated as bursa weight/body weight x Diego, CA). The frozen bursae were processed a s 1000. The vaccinated group was considered protected described earlier and probed for antigen detection by if all bursa/body weight ratios were equal or higher than AC-ELISA (Synbiotics, San Diego, CA). Fixed tissues 2SD (standard deviation) of the non-vaccinated, nonwere sectioned at American Histolabs (Gaithersburg, challenged control group. The mean for the SPF control MD) and stained by hematoxylin-eosin (HE).
(
group D) was 5.35 (2SD=2.48). Thus, all SPF
Virus neutralization assay (VN): Serum samples were protected. Additionally, vaccinated broilers were also heat-inactivated at 56 C for 1 h and diluted in serial twoconsidered fully protected. o fold dilutions. Each dilution was mixed with 100 TCID Table 2 also shows results from antigen detection 50 of rIBDV and incubated for 1 h at 37 C. The mixture was assessed by AC-ELISA (Synbiotics, San Diego, CA) o added to 85-90% confluent monolayer of Vero cells, seven days post-challenge. IBDV antigen was detected grown in 96-well tissue culture plates (Costar, Ithaca, in two SPF birds that were vaccinated with full dose of NY). All plates were incubated for 5-6 days until the the vaccine. Viral antigens could not be detected in the presence of CPE was detected in the virus control wells.
BF of birds that received half dose of the vaccine or in Normal serum from SPF birds was used as a negative broilers that received full dose. Antigen was detected in control and a polyclonal anti-IBDV (SPAFAS) was used SPF challenge control group (11/12). As expected, no as a positive control. Anti-IBDV titers were determined 5-IBDV antigen could be detected in the negative control 6 days later, averaged, and expressed as log .
birds (group D, and G), whereas non-vaccinated, 2
Results
Vaccine safety -Hatchability and first week survival rates are shown in Table 1 . The hatchability rates in SPF eggs from group A and B were similar (92.5%), indicating that the vaccine is safe even when higher doses were administered. The percentages of hatched birds and first week survival were not significantly different from vaccinated groups and control non-vaccinated. The hatchability rates in broilers were lower than SPF embryos. However, we do not believe the vaccine caused these changes, since non-vaccinated birds also exhibited lower hatchability (88.8%). We attributed it to stress caused by temperature shock during transportation. Embryonated eggs were removed from incubators at 37 C and transported at 22 C for 2 h. The o o vaccinated birds with either dose were considered challenged broilers (8/9) were positive by AC-ELISA at 10 days post-challenge.
Antibody responses:
The antibody responses a s measured by commercial ELISA are shown in Table 2 as geometric mean titer. At two weeks post-vaccination, all vaccinated groups had significantly higher antibody titers (p<0.05) than non-vaccinated groups by either test. As expected, all non-vaccinated SPF birds had negative titers for IBDV at 2 weeks post-vaccination. The nonvaccinated, commercial broilers had maternal antibody titers ranging from 455 to 5455 at 2 weeks of age. At 10 days post-challenge, all SPF vaccinated groups (full and half dose) showed significantly (p<.05) higher titers than the s ame groups at two weeks post-vaccination. However, broilers receiving a full vaccine dose did not show an antibody increase after challenge as measured three weeks of age (Sharma and Lee, 1983) . Efficacy by ELISA. Antibody responses at 2 weeks postvaccination in SPF birds that received half dose of the vaccine were relatively higher than SPF birds vaccinated with a full dose. The level of protective maternal antibodies in the non-vaccinated, unchallenged broilers seemed to wane slightly after challenge. Antibody responses were not detected in SPF non-vaccinated, challenged control birds after 10 days of challenge. This result is expected considering that a primary immune response would take at least 2 weeks to be detected. The results from virus neutralization assay are expressed as Log in Table 2 . All vaccinated groups 2 showed protective levels (between 4-6 Log ) o f 2 antibodies 2 weeks post-vaccination. Non -vaccinated control broilers showed maternal antibody levels (4.8 Log ) lower than normal for the first few weeks of life. All 2 control groups continued to exhibit only low levels of antibodies 10 days post-challenge. As expected, all vaccinated SPF birds showed higher humoral responses after challenge. Vaccinated broilers also showed higher antibody response 10 days postchallenge (7.5 to 9.46).
Histopathology:
The averages of microscopic lesions are shown in Table 2 . At 2 weeks post-vaccination, birds from the control and treatment groups that received either full dose or half dose did not show microscopic lesions in the BF. At 10 days post-challenge, SPF nonvaccinated birds that were challenged showed severe lymphocyte depletion, undulation in the epithelium, intra and interfollicular epithelial cysts, and degeneration of follicular structure (Fig. 1A, Table 2 group C). SPF birds that received full dose of the vaccine (Fig. 1B) showed a mild degree of B-cell depletion, localized in a few follicles. The lesion score for this group was 2.0. SPF birds vaccinated with a half dose of the vaccine did not show histopathological lesions in the bursa (Fig. 1C,  Table 2 group B). The control non-vaccinated, challenged broilers showed bursal lesions. However, they were much milder than SPF challenged controls (Fig. 1D, Table 2 group F) . In addition, broilers that received a full dose of the vaccine showed normal bursae after 10 days post IBDV challenge (Fig. 1F , Table  2 group E). The spleens of SPF non-vaccinated, challenged birds showed hemorrhages and lymphocytic depletion. Nonoccurred, the avian immune system was not fully vaccinated broilers that were challenged showed a milder but more generalized reduction of lymphocytes throughout the entire organ. No lesions were observed in the spleens from vaccinated groups (data not shown).
Discussion
IBD in chickens was first described in 1962 (Cosgrove, 1962) . IBDV is a lymphotropic virus able to cause mainly humoral immunosuppresion in chickens infected before studies with commercial live vaccines in ovo against IBDV caused acute clinical signs of the disease when administered in a full dose. Additionally, hatchability was severely decreased (Sharma et al., 2001) . Attempts to administer commercial vaccines in a lower dosage induced less mortality, however, microscopic bursal lesions persisted (Lukert and Saif, 1997) . In addition, since 1980 new subtypes of serotype I, called 'variant strains' have been isolated in the US (Snyder et al., 1988) . Active or passive immunity mediated b y vaccination with classic strains do not protect against variant strains (Rosenberger et al., 1985) . In this study, a recombinant live attenuated vaccine that expresses multiple neutralizing epitopes of classical and variant strain of IBDV was evaluated in 18-day-old SPF and commercial embryos. SPF embryos were injected with a full or half dose of the virus through the amniotic cavity. Two weeks post-vaccination, birds were challenged with an IBDV-STC strain. Commercial broilers vaccinated with a full dose and SPF embryos vaccinated with half dose were fully protected. I n addition, no significant microscopic bursal lesions were observed in these groups. On the other hand, SPF birds that received a full dose of the vaccine in ovo exhibited microscopic lesions similar to non-vaccinated, challenged control group. No detrimental effects on hatchability with either dosage used were observed. However, histopathological results suggested that a higher dose of the vaccine given to birds that lack sufficient maternal antibody might still be virulent even though clinical signs of IBD were not observed. Our findings agree with previous research in SPF and broiler embryos vaccinated with three commercial intermediate vaccines in ovo. Microscopic bursal lesions were observed even when half of the recommended dose was used (Giambrone et al., 2001) . In a previous report, microscopic lesions were not observed when a full dose of rIBDV live attenuated virus was used to vaccinate two-week-old chickens ocularly (Liu, 2003) . In this study, bursal lesions were observed in SPF birds, lacking maternal antibodies that received a full dose of the vaccine when delivered in ovo. At 10 and 15 days of embryonation, prebursal stem cells are migrating via the blood supply from the spleen to the BF (Masteller and Thompson, 1994) . Consequently, a t eighteen days of incubation, when in ovo vaccination developed and a viral infection that targets this organ may have caused irreversible damage. A second aim of this study was to evaluate the efficacy of this chimeric virus as a potential vaccine in the presence of maternal antibodies. Commercial broilers were from breeder flocks vaccinated with classic and variant strains of IBDV. Vaccinated broilers had significant higher antibody titers than non-vaccinated broiler control group at two weeks post vaccination. According to (half dose) of rD78GLSNSÄ. A) non-vaccinated, challenged SPF, shows severe lymphocytic necrosis and heterophilic inflammation; B) vaccinated (full dose) and challenged SPF birds shows lymphocytic depletion (indicated by arrows); C) vaccinated (half dose) and challenged SPF shows no visible microscopic lesions; D) non-vaccinated, challenged broiler shows lymphocytic necrosis and loss of follicular structure; E ) unvaccinated, and non-challenged control broiler shows no microscopic lesions; F) vaccinated (full dose) and challenged broiler shows no microscopic lesions. Lutticken et al., 1994 , these findings indicate that the Liu, M., 2003. Pathogenesis and apoptosis study o f vaccine was able to breakthrough maternal antibody barrier and seroconvert. Similar results were obtained in broilers vaccinated with a chimeric IBDV vaccine 14 days post-vaccination (Mundt et al., 2003) . However in their studies, the challenge using classic and variant viruses induced chronic lesions in BF of vaccinated broilers with a chimeric virus expressing classic and variant epitopes of GLS and D78 IBDV strains (Mundt et al., 2003) .
The use of the invention: The novelty of this work is its use in ovo to vaccinate commercial broilers in the presence of maternal immunity against IBDV. This study suggests the potential use of rD78GLSNSÄ as a vaccine candidate for in ovo delivery. This vaccine was shown to be safe, highly immunogenic, and protective against STC-IBDV challenge.
